Login to Your Account



Washington Roundup

New Labeling May Signal Trouble for Vivus' Qnexa

By Mari Serebrov


Monday, March 7, 2011
WASHINGTON – The FDA's call for more explicit labeling about birth defects for topiramate is not the news Vivus Inc. wanted to hear.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription